维生素D3通过TRPV1-MAPK信号通路调解性结肠炎的改善
Keke Zhao1, Jian Li1, Yersen Asai1
1The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Frontiers in immunology
|February 16, 2026
概括
维生素D3 (VD3) 通过降低TRPV1-MAPK通路的调节,减少炎症并恢复肠道屏障功能,从而防止性结肠炎 (UC). 这为UC患者提供了新的治疗途径.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 性结肠炎 (UC) 是一种复杂的炎症性肠病,其病因不明.
- 过渡受体潜在瓦尼洛伊德1 (TRPV1) 和基激活蛋白激酶 (MAPK) 途径与炎症有关.
- 通过这些途径在UC中维生素D3 (VD3) 的潜在保护作用尚不清楚.
研究的目的:
- 研究TRPV1-MAPK通路在UC中的作用.
- 通过调节这种途径来评估VD3对UC的治疗效果.
- 探索VD3对平衡和肠道屏障功能的影响.
主要方法:
- 从UC患者和硫酸 (DSS) 诱导的动物中检查了结肠组织.
- 评估VD3干预对疾病活动,结肠组织学和细胞亡的影响.
- 分析了TRPV1和MAPK通路组件的基因/蛋白质表达.
- 使用免疫光检测TRPV1定位在巨细胞上,并测量血清水平.
主要成果:
- 在UC模型中,TRPV1-MAPK通路被上调.
- VD3治疗改善了UC表型,减轻了体重减轻,改善了结肠组织学.
- VD3降低了TRPV1的表达,特别是在巨细胞上,并调节了平衡.
- VD3通过上调奥克卢丁和木辛的调节抑制了促炎细胞因子,并恢复了肠道屏障功能2.
结论:
- 通过调节TRPV1-MAPK通路,VD3在UC中具有保护作用.
- VD3调节免疫反应和肠道屏障功能,为UC提供了一种新的治疗策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
544
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
544
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
915
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
915
Inflammatory Bowel Disease I: Ulcerative Colitis
1.2K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.2K
Inflammatory Bowel Disease IV: Pharmacological Management
795
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
795
Peptic Ulcer Disease II: Pathophysiology
2.3K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.3K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.3K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.3K


